A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

← catalyst calendar

NCT07723248 · readout ≤ 589 d

Sponsored by ORIC Pharmaceuticals (industry) · ORIC — their whole pipeline →. With Bayer.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

600estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

Jul 2026

estimated

When the study began enrolling

Primary completion

Mar 2028

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Sep 2030

estimated

The whole study's end, after follow-up

First posted

2026-07-23

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-23

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Metastatic Castration Resistant Prostate Cancer

Interventions

Drug: Rinzimetostat — also filed as ORIC-944
Drug: Darolutamide — also filed as Nubeqa
Drug: Enzalutamide — also filed as Xtandi
Drug: Docetaxel — also filed as Taxotere

Primary outcome

what the primary-completion date above is the date OF

Radiographic Progression Free Survival assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3)

measured Randomization up to ~2 years

Permalink · ORIC's whole pipeline · Catalyst calendar · Every registered study · What changed